Onco-Innovations Builds Momentum on Drug Manufacturing, AI Deals, and Nasdaq Ambitions

Onco-Innovations advances PNKP inhibitor ONC010 to Phase I, secures AI deals with AstraZeneca and GSK, prepares Nasdaq listing.

Onco-Innovations has rolled out a flurry of operational updates that span drug development, artificial intelligence partnerships, and capital markets strategy – signaling a company that is pulling multiple levers at once. The biotech, valued at just a fraction of its 52-week high of €1.49, saw its stock change hands at around €0.64 on the day, having added roughly 90% over the past 30 days and about 60% on a monthly basis. Annualized volatility sits near 132%.

At the heart of the therapeutic push is A83B4C63, a PNKP inhibitor delivered via a proprietary nanoparticle micelle system called ONC010. Toronto-based Nucro-Technics has started liquid chromatography–mass spectrometry analysis of the compound in biological samples from ongoing animal-model studies, a critical step for refining dosing strategies and building the data package needed for an investigational new drug application. Meanwhile, Dalton Pharma Services in Toronto is scaling production of the precursor A83 to around 1,560 grams and is running a non?GMP synthesis of A83B4C63 at the two-kilogram level – work that feeds directly into the chemistry, manufacturing, and controls program for IND studies.

Parallel to these laboratory advances, Avance Clinical is coordinating the documentation for a future FDA interaction, including a pre?IND meeting to align the study design with regulatory expectations. Onco-Innovations has also established an Australian subsidiary to qualify for the country’s R&D tax incentive, which refunds up to 43.5% of eligible research spend. Contracts are already in place with RDI Partners and Avance Clinical, and submissions to the Human Research Ethics Committee and the TGA?CTN pathway are being prepared. The target is a Phase I trial in 2026.

The company is not limiting its activity to the lab. Inka Health, its wholly owned subsidiary, has struck two separate alliances with global pharma heavyweights. With AstraZeneca, Inka Health will use multimodal artificial intelligence to improve prediction of clinical outcomes in oncology under the PROmAI umbrella. Close on its heels came an agreement with GlaxoSmithKline to develop methods that make clinical trial results more transferable to real?world populations and health?care systems. The underlying data infrastructure relies on OneMedNet’s iRWD platform, built on Palantir’s Foundry software, which supplies real?world oncology data from the United States. Onco-Innovations is using that pipeline to train its own SynoGraph AI system, designed to forecast the efficacy and safety of potential new cancer treatments.

On the capital markets side, the company has appointed a US investment banker and is preparing a secondary listing on the Nasdaq. It also filed a preliminary shelf prospectus in four Canadian provinces in February 2026 that, once finalized, would permit the issuance of various securities over a 25-month period – though both moves remain subject to regulatory approval.

Whether the Phase I study indeed launches next year hinges on how smoothly the ongoing bioanalytical and manufacturing efforts coalesce into a comprehensive IND dossier. For now, Onco-Innovations is keeping its pipeline, partnerships, and financing plans moving in concert – a high?stakes balancing act in a corner of the market that has already shown it can swing sharply.